In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Late breaking trial III - Innovative and device therapy
Session

Event : Heart Failure 2018

Topic : Device Therapy

  • Session type : Special Session
  • Date : 28 May 2018
  • Time : 08:30 - 10:00

12 presentations in this session

Discussion - CRT Survey II

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy

Long-term outcome in the pivotal MOMENTUM 3 trial: medical resource use and cost implications

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy
  • Speaker : M Mehra (Boston,US)

Discussion - MOMENTUM 3

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy

Discussion - FIX-5C and the EU registry

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy

Discussion - EchoCRT

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy

Surgical ablation of the right greater splanchnic nerve (GSN) for the treatment of HFpEF: a prospective, first-in-human clinical trial

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy
  • Speaker : P Ponikowski (Wroclaw,PL)

The v-wave shunt for left atrial decompression in patients with advanced chronic heart failure: fim safety and feasibility study

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy
  • Speaker : S Anker (Berlin,DE)

Discussion - The v-wave shunt for left atrial decompression

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are